The Broad Spectrum Receptor Tyrosine Kinase Inhibitor Dovitinib Suppresses Growth of BRAF Mutant Melanoma Cells in Combination with Other Signaling Pathway Inhibitors

BRAF inhibitors have revolutionized treatment of mutant BRAF metastatic melanomas. However, resistance develops rapidly following BRAF inhibitor treatment. We have found that BRAF-mutant melanoma cell lines are more sensitive than wild-type BRAF cells to the small molecule tyrosine kinase inhibitor...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pigment Cell Melanoma Res
Auteurs principaux: Langdon, Casey G., Held, Matthew A., Platt, James T., Meeth, Katrina, Iyidogan, Pinar, Mamillapalli, Ramanaiah, Koo, Andrew B., Klein, Michael, Liu, Zongzhi, Bosenberg, Marcus W., Stern, David F.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5215495/
https://ncbi.nlm.nih.gov/pubmed/25854919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12376
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires